MétaCan
Menu
Back to cohort
Record W4281651554 · doi:10.1016/j.eururo.2022.05.007

Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study

2022· article· en· W4281651554 on OpenAlexafffundabout
Daniel Burns, Ezequiel Anokian, Edward J. Saunders, Robert G. Bristow, Michael Fraser, Jüri Reimand, Thorsten Schlomm, Guido Sauter, Benedikt Brors, Jan O. Korbel, Joachim Weischenfeldt, Sebastian M. Waszak, Niall M. Corcoran, Chol‐Hee Jung, Bernard J. Pope, Christopher M. Hovens, Géraldine Cancel‐Tassin, Olivier Cussenot, Massimo Loda, Chris Sander, Vanessa M. Hayes, Karina D. Sørensen, Yong‐Jie Lu, Freddie C. Hamdy, Christopher S. Foster, Vincent J. Gnanapragasam, Adam P. Butler, Andy G. Lynch, Charlie E. Massie, Dan J. Woodcock, Colin S. Cooper, David C. Wedge, Daniel S. Brewer, Zsofia Kote‐Jarai, Rosalind A. Eeles

Bibliographic record

VenueEuropean Urology · 2022
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Diagnosis and Treatment
Canadian institutionsPrincess Margaret Cancer CentreUniversity Health NetworkUniversity of TorontoOntario Institute for Cancer Research
FundersNational Cancer InstituteNIHR Cambridge Biomedical Research CentreCancer Research UK Cambridge Institute, University of CambridgeNIHR Oxford Biomedical Research CentreCanadian Institutes of Health ResearchHutchison Whampoa LimitedLi Ka Shing FoundationSyöpäjärjestötNational Institute for Health and Care ResearchWeill Cornell Medical CollegeCentre Léon BérardTampereen YliopistoNational Health and Medical Research CouncilCancer Research InstituteInstitut National Du CancerInstitut National de la Santé et de la Recherche MédicaleRosetrees TrustProstate Cancer Foundation of AustraliaNational Cancer Research InstituteRoyal Marsden NHS Foundation TrustCancer Research UKBiotechnology and Biological Sciences Research CouncilProstate Cancer FoundationJohns Hopkins UniversityMovember FoundationNovo Nordisk FondenAcademy of FinlandMasonic Charitable Foundation
KeywordsMedicineProstate cancerProstateBiochemical recurrenceGermlineOncologyCancerProstatectomyInternal medicineGynecologyUrologyGeneGenetics

Abstract

fetched live from OpenAlex

BACKGROUND: Germline variants explain more than a third of prostate cancer (PrCa) risk, but very few associations have been identified between heritable factors and clinical progression. OBJECTIVE: To find rare germline variants that predict time to biochemical recurrence (BCR) after radical treatment in men with PrCa and understand the genetic factors associated with such progression. DESIGN, SETTING, AND PARTICIPANTS: Whole-genome sequencing data from blood DNA were analysed for 850 PrCa patients with radical treatment from the Pan Prostate Cancer Group (PPCG) consortium from the UK, Canada, Germany, Australia, and France. Findings were validated using 383 patients from The Cancer Genome Atlas (TCGA) dataset. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: A total of 15,822 rare (MAF <1%) predicted-deleterious coding germline mutations were identified. Optimal multifactor and univariate Cox regression models were built to predict time to BCR after radical treatment, using germline variants grouped by functionally annotated gene sets. Models were tested for robustness using bootstrap resampling. RESULTS AND LIMITATIONS: Optimal Cox regression multifactor models showed that rare predicted-deleterious germline variants in "Hallmark" gene sets were consistently associated with altered time to BCR. Three gene sets had a statistically significant association with risk-elevated outcome when modelling all samples: PI3K/AKT/mTOR, Inflammatory response, and KRAS signalling (up). PI3K/AKT/mTOR and KRAS signalling (up) were also associated among patients with higher-grade cancer, as were Pancreas-beta cells, TNFA signalling via NKFB, and Hypoxia, the latter of which was validated in the independent TCGA dataset. CONCLUSIONS: We demonstrate for the first time that rare deleterious coding germline variants robustly associate with time to BCR after radical treatment, including cohort-independent validation. Our findings suggest that germline testing at diagnosis could aid clinical decisions by stratifying patients for differential clinical management. PATIENT SUMMARY: Prostate cancer patients with particular genetic mutations have a higher chance of relapsing after initial radical treatment, potentially providing opportunities to identify patients who might need additional treatments earlier.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow), Insufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.024
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.017
GPT teacher head0.263
Teacher spread0.246 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations6
Published2022
Admission routes3
Has abstractyes

Explore more

Same venueEuropean UrologySame topicProstate Cancer Diagnosis and TreatmentFrench-language works237,207